Moderna Competitors and Similar CompaniesClear all

Regulus Therapeutics's competitors and similar companies include Alnylam Pharmaceuticals and Celyad.
Regulus Therapeutics
Regulus Therapeutics
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Celyad
Celyad
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
Founding Date
Founding Date
2007
Founding Date
2002
Founding Date
2007
Type
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Paris, FR
Milan, IT
Tokyo, JP
Amsterdam, NL
Stockholm, SE
Zug, CH
see more
Locations
Mont-Saint-Guibert, BE HQ
New York, US
Employees
Employees
2462% decrease
Employees
1,32324% increase
Employees
35
Valuation ($)
Valuation ($)
158.4 m
Valuation ($)
19 b
Valuation ($)
14.8 m
Twitter followers
Twitter followers
790
Twitter followers
16.3 k
Twitter followers
2.4 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
23
Number of tweets (last 30 days)
2
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
3
Average likes per tweet (last 30 days)
1
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
86.96%
Percentage of tweets with engagement (last 30 days)
50%

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$1.8b (FY, 2023)
Revenue (est.)
€102k (FY, 2023)
Cost of goods
Cost of goods
N/A
Cost of goods
$268.2m (FY, 2023)
Cost of goods
€69k (FY, 2023)
Gross profit
Gross profit
N/A
Gross profit
$1.6b (FY, 2023)
Gross profit
€1.4m (FY, 2023)
Net income
Net income
($30m) (FY, 2023)
Net income
($440.2m) (FY, 2023)
Net income
(€8.4m) (FY, 2023)

Funding

Total funding raised
Total funding raised
$ 10m
Total funding raised
$ 1.5b
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Alnylam Pharmaceuticals
HQ
Cambridge, US
Employees
1,323↑ 24% increase

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

View company
Celyad
HQ
Mont-Saint-Guibert, BE
Employees
35

Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.

View company